ProQR Therapeutics (PRQR) Competitors $1.74 -0.11 (-5.95%) Closing price 04:00 PM EasternExtended Trading$1.74 0.00 (0.00%) As of 04:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends PRQR vs. BCAX, CVAC, ORGO, ABUS, PRAX, NUVB, PHAR, SION, LENZ, and CRMDShould you be buying ProQR Therapeutics stock or one of its competitors? The main competitors of ProQR Therapeutics include Bicara Therapeutics (BCAX), CureVac (CVAC), Organogenesis (ORGO), Arbutus Biopharma (ABUS), Praxis Precision Medicines (PRAX), Nuvation Bio (NUVB), Pharming Group (PHAR), Sionna Therapeutics (SION), LENZ Therapeutics (LENZ), and CorMedix (CRMD). These companies are all part of the "pharmaceutical products" industry. ProQR Therapeutics vs. Bicara Therapeutics CureVac Organogenesis Arbutus Biopharma Praxis Precision Medicines Nuvation Bio Pharming Group Sionna Therapeutics LENZ Therapeutics CorMedix ProQR Therapeutics (NASDAQ:PRQR) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, analyst recommendations, media sentiment, profitability and earnings. Do institutionals and insiders believe in PRQR or BCAX? 32.7% of ProQR Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer PRQR or BCAX? In the previous week, ProQR Therapeutics had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 10 mentions for ProQR Therapeutics and 8 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.83 beat ProQR Therapeutics' score of 0.81 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings & valuation, PRQR or BCAX? Bicara Therapeutics has lower revenue, but higher earnings than ProQR Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProQR Therapeutics$17.88M7.95-$30.43M-$0.32-5.44Bicara TherapeuticsN/AN/AN/AN/AN/A Do analysts rate PRQR or BCAX? ProQR Therapeutics presently has a consensus price target of $9.17, indicating a potential upside of 426.82%. Bicara Therapeutics has a consensus price target of $36.50, indicating a potential upside of 173.42%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProQR Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is PRQR or BCAX more profitable? Bicara Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -134.31%. Bicara Therapeutics' return on equity of 0.00% beat ProQR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ProQR Therapeutics-134.31% -71.58% -19.70% Bicara Therapeutics N/A N/A N/A Does the MarketBeat Community prefer PRQR or BCAX? ProQR Therapeutics received 322 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 61.85% of users gave ProQR Therapeutics an outperform vote. CompanyUnderperformOutperformProQR TherapeuticsOutperform Votes33461.85% Underperform Votes20638.15% Bicara TherapeuticsOutperform Votes12100.00% Underperform VotesNo Votes SummaryProQR Therapeutics beats Bicara Therapeutics on 7 of the 13 factors compared between the two stocks. Remove Ads Get ProQR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRQR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRQR vs. The Competition Export to ExcelMetricProQR TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$142.12M$6.93B$5.63B$7.93BDividend YieldN/A2.72%4.89%4.05%P/E Ratio-5.446.1123.6418.73Price / Sales7.95219.83371.04119.11Price / CashN/A65.6738.0534.64Price / Book3.166.616.854.19Net Income-$30.43M$139.99M$3.19B$247.07M7 Day Performance-10.31%-2.38%5.32%-2.84%1 Month Performance-23.35%-8.96%-1.07%-10.77%1 Year Performance-25.32%-5.03%12.34%0.47% ProQR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRQRProQR Therapeutics2.6381 of 5 stars$1.74-5.9%$9.17+426.8%-9.8%$142.12M$17.88M-5.44180Earnings ReportAnalyst UpgradeNews CoveragePositive NewsBCAXBicara TherapeuticsN/A$12.70-4.5%$41.20+224.4%N/A$691.08MN/A0.0032Analyst ForecastLockup ExpirationNews CoverageCVACCureVac4.0245 of 5 stars$3.08-0.6%$10.00+224.7%-7.0%$689.55M$543.28M5.601,172ORGOOrganogenesis3.1066 of 5 stars$5.41-12.9%$5.00-7.6%+78.9%$680.18M$455.04M-90.17950High Trading VolumeABUSArbutus Biopharma2.0262 of 5 stars$3.42-0.9%$5.50+60.8%+18.6%$648.06M$6.74M-7.9590Analyst DowngradeShort Interest ↑News CoveragePRAXPraxis Precision Medicines2.7904 of 5 stars$33.55-13.1%$123.80+269.0%-29.3%$625.31M$1.61M-3.26110Short Interest ↓High Trading VolumeNUVBNuvation Bio2.5487 of 5 stars$1.83-7.4%$8.20+349.3%-3.9%$614.24M$2.16M-0.8460Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumePHARPharming Group2.5884 of 5 stars$9.02+3.9%$27.00+199.5%-32.7%$613.30M$285.75M-34.67280Earnings ReportShort Interest ↓News CoverageGap UpSIONSionna TherapeuticsN/A$14.41+4.6%N/AN/A$612.73MN/A0.0035LENZLENZ Therapeutics2.3622 of 5 stars$21.54-1.3%$35.40+64.3%N/A$592.37MN/A0.00110CRMDCorMedix1.5369 of 5 stars$9.59-7.4%$15.67+63.4%+220.8%$581.89M$12.26M-11.8430News Coverage Remove Ads Related Companies and Tools Related Companies Bicara Therapeutics Competitors CureVac Competitors Organogenesis Competitors Arbutus Biopharma Competitors Praxis Precision Medicines Competitors Nuvation Bio Competitors Pharming Group Competitors Sionna Therapeutics Competitors LENZ Therapeutics Competitors CorMedix Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRQR) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProQR Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share ProQR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
